Supriya Lifescience Limited conducted its Q4 FY26 Earnings Conference Call on May 28, 2026. The company reported its highest-ever revenue and EBITDA performance, with Q4 FY26 revenue reaching INR277 crores and full-year FY26 revenue at INR828 crores, a 18.9% year-on-year growth. The Lote facility received a significant regulatory milestone with a USFDA ‘Voluntary Action Indicated’ classification.
Supriya Lifescience Q4 FY26 Earnings Call Summary
On May 28, 2026, Supriya Lifescience Limited held its Q4 FY26 Earnings Conference Call, where management provided an update on the company’s financial performance and strategic initiatives. Dr. Satish Wagh, Executive Chairman and Whole-Time Director, announced a significant regulatory milestone for the Lote facility, which received the USFDA’s Establishment Inspection Report (EIR) with a ‘Voluntary Action Indicated’ classification following a surprise inspection in February 2026.
Financial Highlights and Performance
The company reported its highest-ever revenue and EBITDA performance for the year. For the fourth quarter of FY26 (Q4 FY26), revenue stood at INR277 crores, a substantial 50% increase year-on-year from INR184 crores in Q4 FY25. EBITDA for Q4 FY26 was INR98 crores, up 44% year-on-year, with an EBITDA margin of 35.5%. Profit After Tax (PAT) for the quarter was INR74 crores, up from INR50 crores in Q4 FY25.
For the full financial year FY26, revenue grew by 18.9% year-on-year to INR828 crores, aligning with the guided growth of approximately 20%. EBITDA for FY26 was INR294 crores, a 13% growth, with margins at a robust 35.5%, surpassing the guided range of 33% to 35%. PAT for FY26 was INR209 crores.
Key Growth Drivers and Product Launches
The export segment continues to be a key growth driver, contributing 82% of the financial year revenues, with Europe showing a strong 40% share. Backward integration initiatives progressed to 76% in FY26. New product launches in FY26 included a key cardiovascular product contributing to Q4 FY26 and an ADHD product with strong demand in LATAM and Europe. A liquid anaesthetic product was also commercialized.
For FY27, the company plans to launch approximately 2 new products in anesthetics and ADHD portfolios to enhance market penetration. The company has secured clearances for the Patalganga land, with phased development set to begin in FY27. Guidance for FY27 includes approximately 20% annual growth in revenue and an EBITDA margin of 33% to 35%, targeting a revenue milestone of INR1,000 crores.
Operational and Regulatory Updates
The company is focusing on expanding regulated markets and strengthening its competitive edge through backward integration and regulatory expertise. Capital expenditure for FY26 was INR152 crores, primarily on the Ambernath facility and other projects. The Patalganga facility is planned with a Phase 1 capex of approximately INR200 crores.
In terms of R&D, Supriya Lifescience has set up two new R&D labs and is focusing on new APIs, niche molecules, and formulations. The company is exploring CMO, CDMO, and CRO opportunities. Management expects continued growth of 20% plus year-on-year, with potential acceleration upon full commercialization of Ambernath and Patalganga.
Market Outlook and Strategy
Management highlighted a ‘China Plus One’ strategy to avoid direct competition within India and focus on export markets. The company is not seeing significant pricing pressure on its main products due to its agile working model and ability to pass on raw material cost increases. The focus remains on regulated markets for higher margins, with semi-regulated markets serving as an entry point for new products.
Regarding the US market, management acknowledged that the current portfolio has a larger presence in Europe and LATAM, but new product launches are expected to increase exposure to the US market over the next 3-4 years.
Outlook for Next Steps
The company anticipates revenue from the GLP-1 product development segment in approximately 2 years. Net working capital days are expected to stabilize between 170 to 180 days. The EBITDA margin is projected to remain between 33% to 35%, considering the ongoing launch of new products in both semi-regulated and regulated markets.
Source: BSE
